Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||CC-122 + Onatasertib|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|CC-122||Avadomide||Avadomide (CC-122) is an immunomodulatory drug analog that targets Cereblon and promotes degradation of several proteins, including Ikaros and Aiolos, leading to decreased B-cell proliferation and decreased tumor angiogenesis (Blood Dec 2014, 124 (21) 3500).|
|Onatasertib||CC-223|ATG-008||mTOR Inhibitor 51||Onatasertib (CC-223) is a selective inhibitor of mTOR that induces apoptosis and growth inhibition in tumor cells (PMID: 25855786, PMID: 31527867).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT02031419||Phase I||CC-122 + Spebrutinib Onatasertib + Spebrutinib CC-122 + Onatasertib Rituximab||Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-cell Lymphoma||Active, not recruiting|